Lodz

• Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults with Type 2 Diabetes M … Ended
  2024-512562-34-00 4 2025-02-24 Type 2 Diabetes Mellitus
• Impact of trimetazidine on endothelial function and biomarkers correlating with the prognosis of heart failure with preserved ejection fract … Ended
  2023-506138-65-00 6 2025-02-20 Heart failure with preserved ejection fraction
• Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study for Moderate to Severe Plaque Psoriasis to Evaluate Efficac … Ended
  2023-508959-39-00 5 2025-02-20 Moderate to Severe Plaque Psoriasis
• A Phase 2, Dose-Ranging Study of LY4100511 (DC-853) in Adult Participants with Moderate-to-Severe Plaque Psoriasis Ended
  2024-512207-39-00 4 2025-01-30 Plaque Psoriasis
• A Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous CT-P13 in … Ended
  2024-510945-32-00 5 2024-12-17 Rheumatoid arthritis
• A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy and safety of oral AP118 … Ended
  2024-514981-37-00 4 2024-12-05 Rheumatoid Arthritis
• A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as … Ended
  2024-511557-21-00 5 2024-11-14 Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia
• Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHIN … Ended
  2023-508812-45-00 10 2024-11-11 Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures
• Lowering of LDL-C with rosuvastatin or single-pill combination rosuvastatin/ezetimibe in high/very high-risk patients with hyperlipidaemia – … Ended
  2023-504914-31-00 11 2024-11-10 Hyperlipidaemia
• A Safety and Tolerability Study of VRDN-001 in Persons with Thyroid Eye Disease (TED) Ended
  2023-507563-19-00 5 2024-11-05 Thyroid eye disease
• A study of efgartigimod PH20 SC given by prefilled syringe in adults with thyroid eye disease Ended
  2023-509198-22-00 5 2024-10-21 Thyroid Eye Disease (TED)
• A clinical trial to evaluate safety, efficacy, and tolerability of abrocitinib in subjects with chronic hand eczema. Ended
  2023-504539-42-00 4 2024-10-20 Moderate to severe chronic hand eczema
• Evaluation of efficacy and safety of 0.1% mometasone furoate cutaneous emulsion compared to its active ingredient-free base and a comparator … Ended
  2024-511583-82-00 5 2024-10-08 Plaque psoriasis
• A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe … Ended
  2024-511360-87-00 5 2024-10-02 hidradenitis suppurativa (HS)
• Phase 2 study to evaluate the efficacy and safety of GSK3915393 in participants with Idiopathic Pulmonary Fibrosis (IPF) Ended
  2023-509371-16-00 4 2024-09-25 Idiopathic Pulmonary Fibrosis
• Multicenter, Prospective, Open-label, Randomized, Crossover Study to Evaluate Pharmacokinetics (PK), Safety, and Tolerability of TAK-881 in … Ended
  2022-502095-23-01 10 2024-09-10 Primary Immunodeficiency Diseases
• A study to test whether BI 1819479 improves lung function in people with idiopathic pulmonary fibrosis (IPF). Ended
  2023-508395-11-00 4 2024-09-10 idiopathic pulmonary fibrosis
• A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutane … Ended
  2023-504942-75-01 5 2024-08-22 Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis with or witho
• Clinical study to evaluate the efficacy and safety of Pioglitazone co-administration in patients with type II diabetes with insufficient gly … Ended
  2023-508924-36-00 5 2024-08-20 Type 2 diabetes mellitus (T2DM)
• A dose-finding trial with LU AG90222 in adults with migraine who have not been helped by prior preventative treatments. Ended
  2023-508821-28-00 4 2024-08-14 Migraine
• A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Modera … Ended
  2023-505433-27-00 5 2024-08-13 Atopic Dermatitis
• A Phase 2 Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejec … Ended
  2023-508736-62-00 4 2024-08-08 Heart failure (HF) with reduced ejection fraction (HFrEF)
• A Phase 2 Clinical Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Preserved Ejecti … Ended
  2023-508737-13-00 4 2024-08-08 chronic heart failure
• A study on the immune response, safety and the occurrence of RSV-associated respiratory tract illness after administration of RSV OA vaccine … Ended
  2023-509455-13-00 11 2024-08-05 Respiratory Syncytial Virus Infections

Showing 673–696 of 898 trials